OCTAVE SPECIALTY GROUP INC

In connection with the preparation of this third quarter Form 10-Q, an evaluation was carried out by Octave's management, with the participation of Octave's Chief Executive Officer and Chief Financial Officer, of the effectiveness of Octave's disclosure controls and procedures (as defined in rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) as of the end of the period covered by this Quarterly Report on Form 10-Q. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives. Based on their evaluation, Octave's Chief Executive Officer and Chief Financial Officer have concluded that, as of September 30, 2026, Octave's disclosure controls and procedures were effective.

Management has formally incorporated ArmadaCare into Octave's program for internal control over financial reporting effective September 1, 2026. Accordingly, ArmadaCare is included in the scope of management's control assessments beginning with the third quarter of 2026.

There were no other changes in our internal control over financial reporting during the first nine months of 2026 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION